Colgate-Palmolive sells products that people use up and then buy again. Toothpaste runs out. Soap runs out. Pet food runs out. The company makes money every single time a consumer reaches for another tube of Colgate, another bottle of Palmolive dish soap, or another bag of Hill's Science Diet for their dog. It sells these products in over 200 countries, which means somewhere in the world someone is buying one of its products at almost every moment of every day. Oral care alone accounts for 44% of total sales, and the company holds a 41.3% share of the global toothpaste market. That is not a niche position. That is the dominant position in one of the most reliably purchased products on earth. The diagram below traces where the money goes.
How Colgate-Palmolive Makes Money
flowchart TD
A["Consumer Demand\nAcross 200+ Countries"] --> B["Omni-Channel Sales\n20.4B Revenue"]
B -->|"44% Oral Care"| C["Oral, Personal,\nHome Care"]
B -->|"23% Pet Nutrition"| D["Hill's Pet Nutrition\n80+ Countries"]
C --> E["Brand Portfolio\n25+ Global Brands"]
D --> E
E --> F["Gross Profit\n60.1% Margin"]
F --> G["Operating Income\n16.2% Margin"]
G --> H["Free Cash Flow\n4.2B Annually"]
H --> I["R&D and Marketing\nInvestment"]
I --> A
H --> J["Supply Chain\nand Innovation"]
J --> E
K["Walmart 11%\nOther Retailers"] --> B
Five years of financial data tell a story of a business that grew steadily, got squeezed, and then clawed its way back. Revenue climbed from $17.4 billion in 2021 to $20.4 billion in 2025. That is consistent, if unspectacular, growth. The more telling number is gross margin, which is the share of each dollar of sales left after paying for materials and manufacturing. In 2022, raw material costs hit hard and gross margin fell to 57.0%. The company fought back through price increases and cost-cutting programs, and by 2024 gross margin had recovered to 60.5%. Free cash flow tells the same story. It dropped from $3.3 billion in 2021 to $2.6 billion in 2022, then rebuilt strongly to $4.2 billion in 2025. The direction of travel on cash is clearly positive.
Free Cash Flow 2021 to 2025 (billions)
Free cash flow dropped sharply in 2022 as raw material costs surged, then recovered to a five-year high by 2025.
Debt tells its own part of the story. Net debt rose to $8.0 billion in 2022, likely reflecting acquisition spending and the cash pressure of that difficult year. Since then the company has paid it down steadily, reaching $5.6 billion by 2025. That is a meaningful improvement in financial flexibility over three years.
$5.6B
Net debt in 2025, down from a peak of $8.0B in 2022
But 2025 also delivered a painful reminder that not every bet pays off. The company wrote down $919 million in assets tied to its skin health business, mostly the Filorga brand, after lower-than-expected growth in China and weaker category performance than anticipated. That charge dragged reported net income down to $2.132 billion from $2.889 billion the year before. Stripping out that one-time hit, the underlying business was essentially flat on operating profit year over year. Growth is real but not fast.
2025
crisis
Skin Health Write-Down
In the fourth quarter of 2025, Colgate-Palmolive recorded a $919 million pretax charge to write down goodwill and intangible assets in its skin health business, primarily the Filorga brand. The company cited lower-than-expected category growth rates and weaker-than-expected performance in China. This was a direct signal that an acquisition had not delivered what was expected of it.
The risks the company faces are not hypothetical. About two-thirds of sales come from outside the United States, across more than 200 countries. Wars, tariffs, currency swings, and political instability in places like Ukraine, Russia, Venezuela, Argentina, Nigeria, and Turkey directly affect revenue and costs. The company's own filings describe foreign exchange volatility as particularly acute in hyper-inflationary economies. When local currencies collapse against the dollar, overseas sales translate into fewer dollars even if local unit volumes hold steady.
What Is Raw Material Volatility?
Colgate-Palmolive buys large quantities of oils, resins, agricultural products, and packaging materials to make its products. The prices of these materials move up and down based on global commodity markets, geopolitical events, and weather. When those prices rise sharply and the company cannot raise its own prices fast enough to keep up, profit margins shrink.
Raw material costs are a persistent threat. The 2022 margin squeeze proved how quickly commodity price swings can eat into profits. The company uses price increases and internal cost-cutting programs to defend its margins, but it admits that in the current environment those strategies may become harder to execute. It also warned that consumers facing rising prices may switch to cheaper private-label alternatives or lower-priced versions of its own products.
41.3%
Colgate's share of the global toothpaste market in 2025, down 0.4 points from 2024
Retailer power is another documented concern. Walmart alone accounts for about 11% of the company's total net sales. A small number of large retailers control shelf space and own consumer shopping data that Colgate-Palmolive itself does not have access to. Those retailers can demand better terms, reduce shelf space, or push their own private-label products. On top of that, the growth of online shopping and social commerce has opened the door to new direct-to-consumer competitors who do not need shelf space at all.
What Is a Talc Lawsuit Risk?
Some manufacturers of talcum powder face lawsuits claiming their products caused health problems. Colgate-Palmolive's filings note it faces uncertain talc-related litigation where outcomes have ranged from case dismissals to very large jury awards. The company also faces potential regulatory bans on certain ingredients including fluoride, titanium dioxide, and PFAS compounds, which could force costly product reformulations.
Product liability adds a layer of legal uncertainty. Talc-related lawsuits carry unpredictable outcomes. Regulatory bodies could ban or restrict ingredients used in current products, forcing reformulations that cost money and can disrupt brand identity. The Filorga write-down is a fresh example of what happens when a premium acquisition runs into unexpected headwinds. The company launched a new productivity program in 2025 estimated to cost between $200 million and $300 million in charges through 2028, signaling that another round of structural cost work is underway.
The company's own outlook section uses the word 'softness' to describe category performance in 2025 and expects that softness to continue into 2026. That is an unusually candid signal from a management team describing its near-term prospects.
The core business, toothpaste and soap and pet food, is mature. Most households in developed markets already use these products. Growth has to come from price increases, emerging markets, premiumisation, or new categories. The skin health push was an attempt at the last of those. It did not go as planned. Hill's Pet Nutrition, which made up 23% of 2025 sales, is the clearest growth engine still firing, though even there volume dipped 0.6% in 2025.
$15.8B
Oral, Personal and Home Care net sales 2025
$4.6B
Hill's Pet Nutrition net sales 2025
Pet nutrition is the smaller segment but it grew 2.9% in 2025 while the core segment grew just 1.0%.
The Bet
Colgate-Palmolive's financial logic holds together only if consumers around the world keep choosing its branded products over cheaper alternatives, even when their own budgets are under pressure. The company holds a 41.3% share of global toothpaste sales and a 32.4% share of global manual toothbrush sales, but those shares are already under modest pressure. If trade tariffs keep raising input costs, if currency moves keep eroding overseas revenue, and if private-label competition keeps gaining shelf space, the pricing power that rebuilt gross margins from 57% to 60% could prove fragile. The bet is that Colgate's brand names are strong enough, and sticky enough, to hold consumer loyalty through the next round of economic stress.
Open question
The company generates $4.2 billion in free cash flow, holds the number one position in global toothpaste, and has paid down debt steadily since 2022. At the same time, it just wrote off nearly $1 billion on a skin health acquisition, warned that category softness will continue into 2026, and faces rising input costs it may not be able to fully pass on to consumers. Can a business with dominant share in mature, slow-growing categories generate enough pricing power and new-category growth to justify the premium that investors typically pay for the stability of its brands?
Compiled · 10-K · FY2025
International Operations and Geopolitical Risk
The company gets about two-thirds of its sales from outside the United States and operates in over 200 countries. Wars, political unrest, trade restrictions, and currency changes in places like Ukraine, Russia, Venezuela, and the Middle East have disrupted supply chains, increased costs for raw materials, and reduced customer demand, with potential for material impact on sales and profits.
Supply Chain and Material Cost Volatility
The company relies on global suppliers for key raw materials like oils, resins, and agricultural products that are subject to price swings. Disruptions from geopolitical events, tariffs, pandemics, and climate issues have increased costs and reduced product availability, and the company's efforts to raise prices or cut costs may not fully offset these increases without losing sales volume.
Key Customer Concentration and Retail Pressure
A small number of large retailers control shelf space and consumer data, exercise significant bargaining power, and can demand higher discounts or exclude the company's products. Loss of a major retailer or significant reduction in sales to one could materially harm the business.
Product Liability and Litigation Risk
The company faces uncertain talc-related lawsuits against manufacturers of talcum powder with outcomes ranging from dismissals to very large jury awards. Product recalls, ingredient bans by regulators (fluoride, titanium dioxide, PFAS), or successful liability claims could require product withdrawals, costly reformulations, and damage brand reputation.
Integration Risk from Recent Impairments
The company took a non-cash charge of $794 million in the fourth quarter of 2025 to write down goodwill and intangible assets in its skin health business, signaling that an acquisition underperformed expectations. Future acquisitions carry similar risk of integration failure, unexpected costs, or requiring additional impairment charges.
10-K Item 1A · Risk Factors
